Home > Author

Blog Posts by Author: Adam Ortlieb

Providers Rate XIFIN 1st in Lab Support and RCM Outsourcing, a Clean Sweep for Overall, Hospital, Diagnostic, and Pathology Categories

The results are in for the industry’s premier independent analysis of revenue cycle management (RCM) vendors and XIFIN is the clear winner. The Black Book Research 2021 Laboratory Support and Revenue Cycle Management Outsourcing report ranks 20 RCM vendors on 18 critical performance criteria, based on validated survey results from 1,570 users. XIFIN earned top scores for overall mean, 10...

Read


Delta Variant Impact on Lab Testing Volumes

The impact of the SARS-CoV-2 Delta variant is increasingly severe. The CDC has determined this strain is nearly twice as contagious as previous variants and two studies indicate Delta patients are more likely to be hospitalized than those infected with Alpha or the original virus strains.1 97.4% of all U.S. COVID-19 cases stem from this variant.2Infection numbers are rising rapidly. On August 11...

Read


Ensuring Oncology Practice Compliance with the No Surprises Act

The adverse impacts of surprise billing have garnered significant national attention, culminating in rare bi-partisan supported legislation that directly impacts community oncology practices. The No Surprises Act was signed into law as part of the Consolidated Appropriations Act of 2021.Surprise billing occurs when patients unknowingly receive either emergency or non-emergency care from an out-of...

Read


Top 3 Challenges in Community Oncology Revenue Cycle Management

Community oncology continues to experience a dramatic shift in market dynamics. Substantive developments include a proliferation of acquisitions, the CMS Merit-Based Incentive Payment System (MIPS) and larger shift to value-based reimbursement models, as well as exploration of precision medicine as the standard of care.Notable changes that directly constrain practice financial health include fee...

Read